| ²é¿´: 415 | »Ø¸´: 3 | |||
| µ±Ç°Ö÷ÌâÒѾ´æµµ¡£ | |||
| µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû | |||
rhett82½ð³æ (СÓÐÃûÆø)
ÆÐÌá±¾ÎÞÊ÷,Ã÷¾µÒà·Ç̨,±¾À´ ...
|
[½»Á÷]
ҩѧ´Ê»ã
|
||
|
ҩѧÃû´Ê£¨ÖÐ-Ó¢£© 6-Á×ËáÆÏÌÑÌÇÍÑÇâø glucose-6-phosphate dehydrogenase Janbon×ÛºÏÖ¢ Janbon's syndrome PPBŨ¶È parts per billion concentration pphmŨ¶È parts per hundred million concentration PPHŨ¶È parts per hundred concentration ppmŨ¶È parts per million concentration °²È«·¶Î§ safety range °²È«ÊÔÑé·¨ innocuity test method °²È«ÏµÍ³ safety coefficient °²Î¿¼Á placebo òüºÏ¼Á chelating agent °Ðϸ°û target cell °×µ°°×΢ÇòÖÆ¼Á albumin microballoons °Ù·ÖŨ¶È percentage concentration °ëºÏ³É¿¹ÉúËØ semisynthetic antibiotics °ë¿¹Ô haptene °ëÊýÖÂËÀ¼ÁÁ¿ half lethal dose ; median lethal dose; LD50 °ëË¥ÆÚ half-life period; half life time °üÒÂÆ¬ coated tablet ±¡Ä¤Ò film-coating ±¥ºÍÈÜÒº saturated solution ±´¿ËÀÕ¶û Becquerel ±»¶¯ÃâÒß passive immunity ±»¶¯×ªÔË passive transport ±À½â¶È disintegration ±À½â¼Á disintegrants ±ØÐè°±»ùËá essential aminoacid ±ØÐèÖ¬·¾Ëá essential fatty acid ±ä̬·´Ó¦ allergy; allergic reaction ±íÃæ»îÐÔ surface activity ±íÃæÕÅÁ¦ surface tension ±ûÖÖÉäÏß gamma rays ²¹Ìå complement ²¹Ìåϵͳ complement system ²»Á¼·´Ó¦ adverse reaction ²»ÍêÈ«¿¹Ô incomplete antigen ²ë¼Á liniments ³¤ÆÚ¶¾ÐÔʵÑé long term toxicity test ³¤Ð§ÖƼÁ prolonged action preparation ³¦¸ÎÑ»· enterohepatic circulation ³¦ÈÜ¿ØÊÍÆ¬ enteric controlled release tablets ³¦ÈÜÒ enteric coating ´¦·½ prescription;recipe ´©Í¸´Ù½ø¼Á penetration enhancers ´ÅÐÔ¿ØÊÍÖÆ¼Á magnetic controlled release dosage form ´ÅÐÔÒ©ÎïÖÆ¼Á magnetic medicinal preparations ´ó·Ö×Ó macromolecule µ¥¿Ë¡¿¹Ìå monoclonal antibody µ¨¼îõ¥Ã¸ cholinesterase µ±Á¿ equivalent weight µ±Á¿¶¨ÂÉ equivalent law µ±Á¿Å¨¶È normality µ±Á¿ÈÜÒº normal solution µÈÕÅÈÜÒº isotonic solution µÍ¾ÛÌÇ oligosaccharides µÍÃܶÈÖ¬µ°°× low density lipoprotein µÎ¶¨ titration µÎ¶¨ÇúÏß titration curve µÎÍè¼Á pill µÝÖÊ transmitter µç½â electrolyzation µç½âÖÊ electrolyte ôú¼Á tincture ¶¨ÏòÒ©ÎïÖÆ¼Á directed pharmaceutical preparations ¶¾Àíѧ toxicology ¶¾ÐÔ·´Ó¦ toxic response; toxic reaction ¶ÌÆÚÖ°©ÊµÑé short term carcinogenic test ¶ÔÒòÖÎÁÆ etiological treatment ¶ÔÓ³Ìå antipode ¶ÔÖ¢ÖÎÁÆ symptomatic treatment ¶à¹¦ÄÜø multifunctional enzyme ¶à¼ÁÁ¿¸øÒ© multiple dose administration ¶àÌÇ polyose ¶àëÄ polypeptide ¶ù²è·Ó°· catecholamine ¶þÖØ¸ÐȾ superinfection ·¢½Í fermentation ·¨¶¨´¦·½ official formula ·¼×廯ºÏÎï aromatic compound ·ÅÉä¶¾Àíѧ radiotoxicology ·ÅÉäÒ©¼Áѧ radiopharmaceutics ·Ç±ØÐè°±»ùËá non-essential amino acid ·ÇÈ¥¼«»¯Ðͼ¡ËÉÒ© nondepolarizer ·Ö×Ó²¡ molecular disease ·Ö×ÓÈÜÒº molecular solution ·Ö×ÓÉúÎïѧ molecular biology ·Ö×ÓÒ©Àíѧ molecular pharmacology ¸¨»ù prosthetic group ¸¨ÁÏ excipients ¸¨Ã¸ coenzyme ¸±×÷Óà side effect ¸½¼Ó¼Á additive ¸ÉÔï¼Á desiccant;drying agent ¸ÎÊ×¹ýЧӦ first pass effect of hepar ¸ÐÊÜÆ÷ receptor ¸ßÃôÐÔ hyperreactivity ¸öÌå²îÒìÐÔ individual differences; individual variation ¸øÒ©·½°¸»ò¸øÒ©ËÙ¶È dosage regimen or dose rate ¸øÒ©¼ä¸ô dosing interval ¹¤ÒµÒ©¼Áѧ industrial pharmacy ¹²¼Û¼ü covalent bond ¹âÁ¿×Ó light quantum ¹ãÆ×¿¹ÉúËØ broad-spectrum antibiotic ¹ýÂË filtration ¹ýÃô¶¾ËØ anaphylatoxin ¹ýÃôÐÔÒ©Îï·´Ó¦ anaphylactic drug reaction ¹ýÑõ»¯Îï superoxide º¬Á¿¾ùÔÈ¶È content uniformity ºËÌǺËËá ribonucleic acid; RNA ºËÜÕËá nucleotide ºÏ²¢ÓÃÒ© drug combination ºÏ³ÉÒ©Îï synthetic drugs ºÏ¼Á mixture ºÛÁ¿ÔªËØ trace element »¯Ñ§·ÖÎö chemical analysis »¯Ñ§ÎïÀíѧ chemical physics »¯Ñ§Ïû¶¾·¨ chemical disinfection »¯Ñ§Ò©ÎïÖÎÁÆ chemotherapy »·¾³Ò©Àíѧ environmental pharmacology »ù±¾Ò©Îï essential drugs »ùÒò gene ¼¤»î¼Á activator ¼¤»î×÷Óà activation ¼¤ËØ hormone ¼¤ËØÔ prohormone ¼±ÐÔ¶¾ÐÔʵÑé acute toxicity test ¼ºÌÇ´¼Ï¸°û¶¾¼Á cytotoxic hexitols ¼ÁÁ¿ dosage; dose ¼ÁÁ¿»òŨ¶ÈµÄÒÀ´æÐÔ dose or concentration dependency ¼ÁÐÍ dosage form ¼ä½ÓÖ°© indirect carcinogenesis ¼äЪÃð¾ú·¨ discontinuous sterilization ¼îÖж¾ alkalosis;alkali-poisoning ½ºÌåÈÜÒºÐÍÒ©¼Á medical colloidal solution ½ÀÓÃÆ¬ chewable tablets ½Í½â glycolysis Þ׿¹×÷Óà antagonism ½â¶¾×÷Óà detoxication ½éÖÊ mediator; transmitter; medium ¾«ÉñÒÀÀµÐÔ psychic dependence ¾çÒ© powerful drug ¾ø¶ÔÖÂËÀ¼ÁÁ¿ absolute lethal dose; LD100 ¿¹¶¾ËØ antitoxin ¿¹¾úÆ× antibacterial spectrum ¿¹Ìå antibody ¿¹ÑªÇå antiserum ¿¹Ò©ÐÔ resistance to drugs ¿¹Ô antigen ¿Ëµ±Á¿ gram-equivalent weight ¿Ëµ±Á¿Êý gram-equivalent number ¿Ë·Ö×Ó gram-molecule; gram-mol ¿Ë·Ö×Ó·ÖÊý molar fraction ¿Ë·Ö×ÓÁ¿ gram molecular weight ¿Ë·Ö×ÓŨ¶È molar comcentratin; molal comcentration ¿ËÔ×Ó gram-atom ¿ØÊÍÖÆ¼Á controlled release preparation ¿ÚÇ»ÄÚ¸øÒ© oral administration ¿ìËÙÄÍÊÜ tachyphylaxis À©É¢ diffusion À©É¢ÏµÊý coefficient of diffusion ÀÛ»ýÄòÅÅйÇúÏß cumulative urinary excretion curves ÀÛ¼ÓЧӦ additive effect Àà¶¾ËØ anatoxin;toxoid Àà¹Ì´¼Í£Ò©×ÛºÏÕ÷ steroid withdrawal syndrome À䲨 cold-storage Àä¶³ freezing;refrigeration Á¿×ÓÒ©Àíѧ quantum pharmacology ÁÙ´²Ò©Àíѧ clinical pharmacology ÁÙ´²Ò©Ñ§ chlinical pharmacy ±»¯Îï halogenide ÂñÖ²¼Á implants ÂýͨµÀ slow pathway ÂýÐÔ¶¾ÐÔʵÑé chronic toxicity test; long term toxicity test ø enzyme Ã¸Ô proenzyme ÃâÒßÒÖÖÆ¼Á immunosuppressant;immuno inhibitor ÃâÒßÔÐÔ immunogenicity ÃâÒßÔöÇ¿¼Á immunoenhancement Ãô¸ÐÐÔ sensitivity Ħ¶û mole Ħ¶û·ÖÊýŨ¶È mol fraction concentration Ħ¶û·Ö×ÓÌå»ý molar volume;mole volume Ħ¶ûŨ¶È molarity Ĭ¿ËË÷Òý the Merck index ÄÍÊÜÐÔ tolerance ÄÍÒ©ÐÔ drug tolerance ÄÚ¶¾ËØ endotoxin ÄÚ¶¾ËØö×ÊÔ¼Á²â¶¨·¨ Limulus Amebocyte Lysate assay for endotoxin ÄÚÏûÐýÌå mesomer Ũ¶È concentration Ƥ·ô¡¢Õ³Ä¤±íÃæ¸øÒ© skin and mucocutaneous administration Ƭ¼ÁÓ²¶È tablet hardness ÆøÄý½º aerogel ÆøÈܽº aerosol ÆøÌå·ÖÎö gas analysis ÆøÎí¼Á aerosol ǰÌåÒ©Îï prodrug ÇÊÄÚ×¢Éä intrathecal injection ȫøÓ븨»ù holonzyme and prosthetic group È˹¤ºÏ³É¿¹Ô artificial antigen È˹¤ÃâÒß artificial immunization ÈËÖÖÒ©Àíѧ ethnopharmacology ÈÕÄÚÍßÃüÃû·¨ Geneva nomenclature ÈܼÁ solvent; dissolvent Èܽâ dissolution; dissolving Èܾúø lysozyme ÈÜѪ hemolysis ÈÜÖÊ solute ÈýôÈËáÑ»· tricarboxylic acid cycle ɱ¾ú»îÐÔ bactericidal activity ɱ¾ú×÷Óà bactericidal effect ÉíÌåÒÀÀµÐÔ physical dependence Éñ¾¶¾ËØ neurotoxin ÉöÉÏÏÙËØÄÜÉñ¾ adrenergic nerve ÉöÉÏÏÙËØÄÜÊÜÌå adrenergic receptor ÉøÍ¸Ñ¹ osmotic pressure Éú³¤ÇúÏß growth curve ÉúÎï°· biogenic amine ÉúÎï°ëË¥ÆÚ biological half life ÉúÎﻯѧ biochemistry ÉúÎï¼î alkaloid ÉúÎïÀûÓÃ¶È bioavailability ÉúÎïͳ¼ÆÑ§ biometrics;biometry ÉúÎïÒ©¼Áѧ biopharmacy ÉúÎïÖÆÆ· biological product ÉúÒ© crude drugs ʱ³½Ò©Àíѧ chronopharmacology ʱ¼ä¸ÐÊÜÐÔ chronosusceptability ʱ¼äÖÎÁÆ chronotherapy ʱЧ¹ØÏµ time-effect relationship ʱֵ chronaxia;chronaxy ʱÖÍ lag time ÊÀ½çÎÀÉú×éÖ¯ World Health Organization; WHO ÊɾúÌå bacteriophage ÊÕÁ²Ò© astringent ÊÖÐÔÒ©Îï chiral drug Ê×¹ýЧӦ first-pass effect ÊÜÌå receptor ÊÜÌ弤¶¯¼Á receptor stimulant ÊÜÌåÞ׿¹¼Á receptor antagonist ˫ä·¨ double-blind technique Ë®½â£¨×÷Óã© hydrolysis ÌÇÒìÉú×÷Óà gluconeogenesis Ìå±íÃæ»ý body surface area Ìå»ý±ÈŨ¶È volume by volume concentration ÌåÒº body fluid ÌåÒºÃâÒß humoral immunity ÌìÈ»¿¹Ìå natural antibody ÌìÈ»¿¹Ô natural antigen ÌìÈ»ÃâÒß natural immunity ÌìȻҩÎï crude drugs; natural drugs µ÷¼Áѧ dispensing pharmacy Í¬Î»ËØ isotope Í»±ä mutation ÍÌÊÉ×÷Óà phagocytosis Íâ¶¾ËØ exotoxin ÍâÏûÐýÌå raceme ÍêÈ«¿¹Ô complete antigen ÍõË® aqua regia; nitrohydrochloric acid ΢Á£Ìåø microsomal enzyme ΢Á¿ÔªËØ trace element ÎÈ̬ѪҩŨ¶È steady state plasma concentration ÎïÀíÒ©¼Áѧ physical pharmaceutics ÎüÈë·¨ inhalation ÎüÊÕËÙÂʳ£Êý absorption rate constant ϸ°ûÃâÒß cellular immunity ÏÙÜÕÁ×Ëá adenosine phosphate ÏÞÖÆÐÔ¾çÒ© restrictive holagogue Ïà¶Ô¸øÒ©¼ä¸ô relative dosage interval Ïà¼Ó×÷Óà additive effect; addition Ïò°Ð¸øÒ© targetable drug delivery Ïû³ýËÙÂʳ£Êý elimination rate constant Ч¼Û potency Ч¼Ûµ¥Î» potency unit Ч¼ÛÇ¿¶È potency ЧӦ effect ЧӦÆ÷ effector ЧӦÎï effector ж¨´¦·½ cipher prescription Ðͬ×÷Óà synergism ÐË·ÜÐÔ excitability Ðò¹áÉè¼Æ sequential design Ðü¸¡Òº suspension Ñ¡ÔñÐÔ selectivity Ѫ¹ÜÄÚ¸øÒ© intravascular administration Ѫ¹ÜÍâ¸øÒ© extravascular administration Ѫ½¬ plasma Ѫ½¬´úÓÃÒº plasma substitute Ѫ½¬µ°°×½áºÏÂÊ plasma protein binding ratio ѪÄÔÆÁÕÏ blood-cerebral barrier ѪÇå serum ѪÈÝÁ¿À©³ä¼Á blood volume expander ѪҩŨ¶È blood concentration ѪҺÄý¹Ì blood coagulation ÑªÒºÖÆÆ· blood products ÑǼ±ÐÔÖж¾ subacute intoxication;subacute poisoning ÑÇÏõËáÑÎÖж¾ nitrite poisoning ÑÛÓÃĤ¼Á ocular inserts Ò©¡ªÊ±°ë¶ÔÊýÇúÏß semi-logarithmic curve of drug-time Ò©¡ªÊ±ÇúÏß drug-time curve Ò©·åŨ¶È peak concentration of drug Ò©·åʱ¼ä peak time of drug Ò©¼ÁµÈЧÐÔ pharmaceutical equivalence Ò©¼Áѧ pharmaceutics Ò©Àíѧ pharmacology Ò©ÃôÊÔÑé drug sensitive test Ò©Æ·¸ºÔðÆÚ allotted date of drug quality ensuring by manufacturer Ò©Æ·¹ÜÀí·¨ drug administration law Ò©Æ·ÅúºÅ drug batch number ҩƷʹÓÃÆÚ limit date of using a drug after its production Ò©Æ·ÓÐЧÆÚ expiry date; date of expiration Ò©Æ·ÖÊÁ¿±ê×¼ drug standard Ò©Îï´úл drug metabolism Ò©Îï´úлø drug metablic enzyme Ò©ÎïµÄÌåÄÚ¹ý³Ì intracorporal process of drugs Ò©ÎﶯÁ¦Ñ§Ä£ÐÍ pharmacokinetics model Ò©Îï·´Ó¦ drug reaction Ò©Îï·Ö²¼ drug distribution Ò©Îï·ÖÎö pharmaceutical analysis Ò©Îﻯѧ pharmaceutical chemistry Ò©ÎïÅÅй drug excretion Ò©ÎïÎüÊÕ drug absorption Ò©ÎïÏ໥×÷Óà drug interaction Ò©ÎïÏû³ý drug elimination Ò©ÎïÐî»ý drug accumulation Ò©Îïѧ pharmacology; materia medica Ò©ÎïÒÅ´«Ñ§ pharmacogenetics ҩЧ¶¯Á¦Ñ§ pharmacodynamics Ò©Ô´ÐÔ¼²²¡ drug-induced diseases ÒÒõ£µ¨¼îÒÒõ£µ¨¼î acetylcholine ÒÒõ£µ¨¼îõ¥Ã¸ acetylcholinesterase ÒÖ¾ú»îÐÔ bacteriostatic activity ÒÖ¾ú×÷Óà bactriostasis Ò칹ø isomerase ÓªÑøËØ nutrient Ó²¸à¼Á plaster ÓÐЧ°ëË¥ÆÚ effective halt ÓÐЧÂÊ effective rate ÓÐЧŨ¶È effective concentration ÓÒÐýÌÇ dextrose ÓÒÐýÌå dextrorotatory form ãмÁÁ¿ threshold dose ÔØÌå carrier Ôíß° saponins Ö¬ÖÊÌå liposome Ö±³¦¸øÒ© rectal administration Ö±ÏßÏà¹Ø linear correlation Ö½ÐÍÆ¬¼Á oral medicaed soluble paper Ö°©ÊµÑé carcinogenic test Ö°©Îï carcinogen Ö»ûÊÔÑé teratogenic test Ö»ûÎï teratogen ÖÂÃôÊÔÑé sensitization test ÖÂÃô×÷Óà sensitization ÖÂËÀÁ¿ fatal dose; lethal dose ÖÆ¼Á preparation ÖÆ¼Áѧ technology of pharmaceutics ÖÆÒ©»¯Ñ§ pharmaceutical chemistry ÖÎÁƵÈЧ£¨Öµ£© therapeutic equivalence ÖÎÁÆÁ¿ therapeutic dose ÖÎÁÆÒ©ÎïÁÙ²â therapeutic drug monitoring; TDM ÖÎÁÆÖ¸Êý therapeutic index TI ÖÎÁÆ×÷Óà therapeutic action Öж¾ intoxication; poisoning ÖлªÈËÃñ¹²ºÍ¹úÎÀÉú²¿Ò©Æ·±ê×¼ Drug Standard of Ministry of Public Health of the People's Republic of China ÖмäÌå intermediate ÖúÂ˼Á filter aid ÖúÈܼÁ complex solubilizer ÖúÐü¼Á suspending agent ×ÔÉíÃâÒß autoimmunity ×é°· histamine ×î´óÄÍÊܼÁÁ¿ maximal tolerable dose; LDO ×î´óÎÞ×÷ÓüÁÁ¿ maxial noneffective dose; EDO ×îСÏÔÖø²îÊý least significant difference ×îСÓÐЧÁ¿ minimal effective dose ×îСÖÂËÀ¼ÁÁ¿ minimal lethal dose;MLD ×óÐýÌÇ levulose ×óÐýÌå levorotatory form ×ô¼Á adjuvant |
» ²ÂÄãϲ»¶
¶ÔÕÕÆ·ÔÚÒ©Æ·Ñз¢ÖеIJ»¿É»òȱÐÔ
ÒѾÓÐ0È˻ظ´
ÎåÒØ´óѧҩÎﻯѧÉúÎïѧÍŶÓ-ÀîÀ¼Çå¿ÎÌâ×éÕÐÊÕµ÷¼ÁѧÉú
ÒѾÓÐ0È˻ظ´
Ò©ÀíѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ76È˻ظ´
Çóµ÷¼Á×Ü·Ö327
ÒѾÓÐ0È˻ظ´
±ê׼ƷµÄ·ÖÀàºÍÓÃ;£¬ÄãÖªµÀ¶àÉÙ£¿
ÒѾÓÐ0È˻ظ´
Çóµ°°×ÍÆ¼ö£¬ÓÃÓÚʵÑé½ÌѧÖе°°×Ò©ÎïµÄ±í´ï
ÒѾÓÐ0È˻ظ´
Çóµ°°×ÍÆ¼ö£¬ÓÃÓÚʵÑé½ÌѧÖе°°×Ò©ÎïµÄ±í´ï
ÒѾÓÐ0È˻ظ´
Çóµ°°×ÍÆ¼ö£¬ÓÃÓÚʵÑé½ÌѧÖе°°×Ò©ÎïµÄ±í´ï
ÒѾÓÐ2È˻ظ´
342Ò»Ö¾Ô¸´ó¹¤ÖÆÒ©×¨Ë¶£¬±¾¿Æ211£¬Çóµ÷¼Á
ÒѾÓÐ0È˻ظ´
¶ÔÕÕÆ·µÄÑ¡ÔñºÍʹÓù淶£¬ÖúÁ¦Ò©Æ·ÖÊÁ¿¹Ü¿Ø
ÒѾÓÐ0È˻ظ´
» ±¾Ö÷ÌâÏà¹ØÉ̼ÒÍÆ¼ö: (ÎÒÒ²ÒªÔÚÕâÀïÍÆ¹ã)

wxmwqr
½ð³æ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 898.8
- É¢½ð: 1
- Ìû×Ó: 253
- ÔÚÏß: 16.1Сʱ
- ³æºÅ: 247223
- ×¢²á: 2006-05-01
- ÐÔ±ð: GG
- רҵ: Ò©Îï·ÖÎö¡¢Ò©Îï´úл
4Â¥2006-05-22 20:55:21
rhett82
½ð³æ (СÓÐÃûÆø)
ÆÐÌá±¾ÎÞÊ÷,Ã÷¾µÒà·Ç̨,±¾À´ ...
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 610.1
- Ìû×Ó: 134
- ÔÚÏß: 8Сʱ
- ³æºÅ: 245946
- ×¢²á: 2006-04-29
- ÐÔ±ð: GG
- רҵ: ҩѧ

2Â¥2006-05-16 17:33:18














»Ø¸´´ËÂ¥
